Clinical trials recruiting for Pancreatic Ductal Adenocarcinoma
64
Recruiting trials
39
US states with sites
32
Countries
14%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Gemcitabine | 11 |
| Nab-paclitaxel | 5 |
| Bevacizumab | 4 |
| Irinotecan | 4 |
| Cetuximab | 3 |
| Leucovorin | 3 |
| Oxaliplatin | 3 |
| gemcitabine + nab-paclitaxel | 3 |
| 5-Fluorouracil | 2 |
| Cisplatin | 2 |
| Folfirinox | 2 |
| Pembrolizumab | 2 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 27 |
| California | 22 |
| New York | 19 |
| Florida | 16 |
| Massachusetts | 13 |
| Michigan | 13 |
| Tennessee | 13 |
| Virginia | 13 |
| Pennsylvania | 12 |
| Colorado | 11 |
| Ohio | 10 |
| Minnesota | 9 |
Top cities
Houston, Texas 22New York, New York 15Boston, Massachusetts 13Fairfax, Virginia 12Nashville, Tennessee 11Duarte, California 9Los Angeles, California 9Philadelphia, Pennsylvania 8Seattle, Washington 8Dallas, Texas 7
Self-screener
Recruiting trials
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- A Study of GV20-0251 in Advanced or Refractory Solid Tumors
- A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
- A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- AB122 Platform Study
- AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening
- Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
- Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
- French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
- Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
- IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
- Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
- Lead-212 PSV359 Therapy for Patients With Solid Tumors
- Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)
- MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
- Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma.
- Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
- Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
- Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
- PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Cancer Detection Consortium
- Pancreatic Cancer Early Detection Consortium
- Pancreatic Cancer Screening Through the Detection of Elastase-1 Combined With Other Examinations
- Pancreatic Cancer Screening in a Population at High Risk
- Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer
- Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer
- Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- Reinforced Pancreaticojejunostomy With or Without glubran2
- SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
- Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
- Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
- Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
- Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
- Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
- TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)
- Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
- Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
- UCSF PANC Cyst Registry
- Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
- [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
- iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
Related conditions
Trials recruiting for Pancreatic Ductal Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870Colorectal cancer 1359Lung cancer 2180Non-small cell lung cancer 507Gastric cancer 91Pancreatic Neoplasms 38Ovarian cancer 118Endometrial cancer 68Triple-negative breast cancer 138PDAC 11
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Pancreatic Ductal Adenocarcinoma trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.